Journal of Cardiac Failure
Volume 16, Issue 3 , Pages 200-206 , March 2010

Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and Diabetes

  • Digish D. Shah, MD

      Affiliations

    • Cedars Sinai Medical Center, Los Angeles, CA
    • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, CA
    • ,
  • Tamara B. Horwich, MD, MS

      Affiliations

    • David Geffen School of Medicine, University of California, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Tamara B. Horwich, MD, MS, Ahmanson-UCLA Cardiomyopathy Center, UCLA Division of Cardiology, 10833 Le Conte Ave. CHS A2-237, Los Angeles, CA 90095. Tel: (310) 825-8816; Fax: (310) 206-9133.

Received 6 May 2009 ,Revised 7 October 2009 ,Accepted 15 October 2009.

References 

  1. MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J. 2008;10:1224–1240
  2. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  3. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241:2035–2038
  4. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996–1002
  5. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27:1879–1884
  6. Stratton IM, Adler AI, Neil HA, Matthews DR, Cull CA, Wright AD, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  7. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668–2673
  8. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007;335:497–507
  9. Koro CE, Bowlin SJ, Weiss SR. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Safe. 2005;14:697–703
  10. Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol. 2007;50:32
  11. Inzucchi SE, Masoudi FA, McGuire DK. Metformin therapy in patients with type 2 diabetes complicated by heart failure. Am Heart J. 2007;154:45
  12. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583–590
  13. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–2351
  14. Melchior WR, Jaber LA. Metformin: an antihyperglycemic agent for treatment of type 2 diabetes. Ann Pharmacother. 1996;30:158–164
  15. Fonarow GC, Stevenson LW, Walden JA, Livingston NA, Steimle AE, Hamilton MA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 1997;30:725–731
  16. Aaronson KD, Mancini DM. Mortality remains high for outpatient transplant candidates with prolonged (>6 months) waiting list time. J Am Coll Cardiol. 1999;33:1189–1195
  17. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–2581
  18. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities- the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374–381
  19. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:480–486
  20. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996;77:1017–1020
  21. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Kober L, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43:771–777
  22. Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure. Diabetes Care. 2007;30:129
  23. Tahrani AA, Varughese GI, Scarpello JH, Hanna FW. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?. BMJ. 2007;335:508–512
  24. Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care. 2004;27:1791–1793
  25. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009;46:145–154
  26. McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur Heart J. 2008;10:703
  27. Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev. 2005;21:51–57
  28. Wong AK, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (London). 2009;116:607–620
  29. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104:403–411
  30. UK Prospective Diabetes Study Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  31. Eshagian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J. 2006;151:91
  32. Kosiborod M, Inzucchi SE, Spertus JA, Wang Y, Masoudi FA, Havranek EP, et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation. 2009;119:1899–1907
  33. Eurich D, Tsuyuki R, Majumdar S, et al. Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials. 2009;10:12

 Dr. Horwich was supported by NIH/NHLBI 1K23HL085097. Dr. Fonarow was supported by the Ahmanson Foundation (Los Angeles, CA) and holds the Eliot Corday Chair in Cardiovascular Medicine and Science.

PII: S1071-9164(09)01132-4

doi: 10.1016/j.cardfail.2009.10.022

Journal of Cardiac Failure
Volume 16, Issue 3 , Pages 200-206 , March 2010

Article Tools

* Image Usage & Resolution